Loading
Eunice Wang is an AML trialist who helped bring FLT3 and menin inhibitors to patients.
Eunice S. Wang is Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. She is an acute myeloid leukaemia trialist known for helping bring FLT3 inhibitors and menin inhibitors to patients, as an investigator on gilteritinib, quizartinib and revumenib studies. Her selected paper reviews crenolanib for FLT3-mutated AML. She leads leukaemia clinical research at Roswell Park and serves on the NCCN acute myeloid leukaemia guideline panel.
| Title | Journal | Year |
|---|---|---|
| Crenolanib for FLT3-mutated AML | Blood Advances | 2021 |
Shares Revumenib, Menin, Acute myeloid leukaemia.
Shares Gilteritinib, FLT3, Acute myeloid leukaemia.
Shares Gilteritinib, FLT3, Acute myeloid leukaemia.
Shares Revumenib, Menin, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares Gilteritinib, FLT3, Acute myeloid leukaemia.
Shares FLT3, Acute myeloid leukaemia.
Shares Revumenib, Menin, Acute myeloid leukaemia.